Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive Ketamine Treatment in Major Depressive Disorder
NCT07396272Phase 2Active, not recruiting
- Start
- Mar 2026
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ketamine in major depressive disorder (MDD). Started Mar 2026; status: active, not recruiting.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07396272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07396272.